Bio-Techne (NASDAQ:TECH) Stock Acquired Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Bio-Techne Co. (NASDAQ:TECH). In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Bio-Techne stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
• Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
• Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

Bio-Techne Trading Down 2.0 %

NASDAQ TECH opened at $58.73 on Friday. The stock has a market cap of $9.28 billion, a P/E ratio of 59.32, a P/E/G ratio of 2.88 and a beta of 1.30. The company has a current ratio of 3.94, a quick ratio of 2.77 and a debt-to-equity ratio of 0.14. Bio-Techne Co. has a 12-month low of $56.60 and a 12-month high of $85.57. The company has a fifty day simple moving average of $66.56 and a two-hundred day simple moving average of $71.47.

Bio-Techne (NASDAQ:TECH) last released its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.03). Bio-Techne had a net margin of 13.22% and a return on equity of 12.73%. On average, analysts forecast that Bio-Techne Co. will post 1.67 earnings per share for the current year.

Bio-Techne Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, February 28th. Shareholders of record on Monday, February 17th were paid a $0.08 dividend. This represents a $0.32 dividend on an annualized basis and a yield of 0.54%. The ex-dividend date of this dividend was Friday, February 14th. Bio-Techne’s dividend payout ratio (DPR) is presently 32.32%.

Institutional Trading of Bio-Techne

A number of institutional investors and hedge funds have recently bought and sold shares of the business. UMB Bank n.a. increased its stake in shares of Bio-Techne by 46.4% during the fourth quarter. UMB Bank n.a. now owns 530 shares of the biotechnology company’s stock worth $38,000 after buying an additional 168 shares during the period. Brooklyn Investment Group purchased a new position in shares of Bio-Techne during the third quarter worth about $39,000. Itau Unibanco Holding S.A. purchased a new stake in shares of Bio-Techne in the 4th quarter valued at about $41,000. Quest Partners LLC acquired a new stake in shares of Bio-Techne in the 3rd quarter valued at about $43,000. Finally, GeoWealth Management LLC purchased a new position in Bio-Techne during the 4th quarter worth approximately $43,000. 98.95% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Evercore ISI started coverage on Bio-Techne in a report on Tuesday, March 18th. They issued an “outperform” rating and a $75.00 price target for the company. KeyCorp boosted their target price on shares of Bio-Techne from $80.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. Baird R W lowered shares of Bio-Techne from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 19th. Robert W. Baird lowered Bio-Techne from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $88.00 to $68.00 in a research note on Wednesday, February 19th. Finally, Scotiabank raised their target price on Bio-Techne from $88.00 to $90.00 and gave the company a “sector outperform” rating in a research report on Thursday, February 6th. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $81.25.

Insiders Place Their Bets

In other news, Director Amy E. Herr sold 1,860 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $65.96, for a total value of $122,685.60. Following the completion of the sale, the director now owns 1,976 shares in the company, valued at approximately $130,336.96. This trade represents a 48.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kim Kelderman sold 13,392 shares of the stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $77.29, for a total value of $1,035,067.68. Following the transaction, the chief executive officer now directly owns 39,004 shares of the company’s stock, valued at approximately $3,014,619.16. This trade represents a 25.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.90% of the stock is currently owned by corporate insiders.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.